文献速递慢性肾脏病水电解质与酸碱

托伐普坦与常染色体显性多囊肾病患者肾脏疼痛:一项随机对照试验的二次分析

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2016-11-14

本研究为TEMPO 3:4试验的二次分析,纳入1445例肾功能保留的常染色体显性多囊肾病(ADPKD)患者,比较托伐普坦与安慰剂对需客观医疗干预的肾脏疼痛事件的影响。托伐普坦组肾脏疼痛事件发生率为10.1%,安慰剂组为16.8%(P<0.001),风险降低36%(HR 0.64,95%CI 0.48-0.86)。

要点

  • 托伐普坦组肾脏疼痛事件发生率10.1%,安慰剂组16.8%(P<0.001),HR 0.64(95%CI 0.48-0.86)。
  • 疼痛事件发生率的降低见于所有严重程度亚组,且不受易感因素影响(交互作用P>0.05)。
  • 托伐普坦的效应至少部分由尿路感染、肾结石和血尿发生率降低所解释。

核心结论

  • 托伐普坦降低了肾脏疼痛事件的发生率,该效应独立于患者易感特征,可能部分归因于ADPKD相关并发症的减少。

研究设计与样本

  • 随机对照试验的二次分析,纳入1445例肾功能保留的ADPKD患者,比较托伐普坦与安慰剂。

主要发现

  • 1445例患者中48.4%为女性,平均年龄39±7岁,平均eGFR 81±22 mL/min/1.73m²,中位总肾脏体积1692(IQR 750-7555)mL,50.9%报告基线有肾脏疼痛史。
  • 尿路感染史、肾结石史或血尿史(均P<0.001)及女性(P<0.001)与肾脏疼痛史显著相关。
  • 托伐普坦组肾脏疼痛事件发生率为10.1%,安慰剂组为16.8%(P<0.001),风险降低36%(HR 0.64,95%CI 0.48-0.86)。
  • 托伐普坦降低疼痛事件发生率见于所有严重程度组,且独立于易感因素(交互作用P>0.05)。
  • 托伐普坦的效应至少部分由尿路感染、肾结石和血尿发生率降低所解释。

局限性

  • 试验对总肾脏体积和肾功能有特定入选标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney pain is a common complication in patients with autosomal dominant polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient group. Because pain is difficult to measure, the incidence of kidney pain leading to objective medical interventions was used in the present study to assess pain. STUDY DESIGN: Secondary analysis from a randomized controlled trial. SETTING & PARTICIPANTS: Patients with ADPKD with preserved kidney function. INTERVENTION: Tolvaptan or placebo. OUTCOMES: Kidney pain events defined by objective medical interventions. MEASUREMENTS: Kidney pain events were recorded and independently adjudicated. Incidence of a first kidney pain event was assessed overall and categorized into 5 subgroups according to severity. RESULTS: Of 1,445 participating patients (48.4% women; mean age, 39±7 [SD] years; mean estimated glomerular filtration rate, 81±22mL/min/1.73m2; median total kidney volume, 1,692 [IQR, 750-7,555] mL), 50.9% reported a history of kidney pain at baseline. History of urinary tract infections, kidney stones, or hematuria (all P<0.001) and female sex (P<0.001) were significantly associated with history of kidney pain. Tolvaptan use resulted in a significantly lower incidence of kidney pain events when compared to placebo: 10.1% versus 16.8% (P<0.001), with a risk reduction of 36% (HR, 0.64; 95% CI, 0.48-0.86). The reduction in pain event incidence by tolvaptan was found in all groups irrespective of pain severity and was independent of predisposing factors (P for interaction > 0.05). The effect of tolvaptan was explained at least in part by a decrease in incidence of urinary tract infections, kidney stones, and hematuria when compared to placebo. LIMITATIONS: Trial has specific inclusion criteria for total kidney volume and kidney function. CONCLUSIONS: Tolvaptan decreased the incidence of kidney pain events independent of patient characteristics predisposing for kidney pain and possibly in part due to reductions in ADPKD-related complications.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Casteleijn NF, Blais JD, Chapman AB, et al. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. Am J Kidney Dis. 2016. PMID: 27856088. doi:10.1053/j.ajkd.2016.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。